Current and Upcoming Clinical Trials

Chronic Myelogenous Leukemia

CGX-635-CML-203: A multi-center phase 2 open-label study to evaluate the efficacy and safety of subcutaneous administration of omacetaxine in the treatment of patients with chronic myeloid leukemia (CML) in chronic, accelerated and blast phase who have failed or are intolerant to two or more tyrosine kinase inhibitors.

CGX-635-CML-202: A multi-center phase 2 open-label study to evaluate the efficacy and safety of subcutaneous administration of omacetaxine in the treatment of patients with chronic myeloid leukemia (CML) in chronic, accelerated and blast phase who have tested positive for the T315I bcr-abl point mutation.

CGX-635-CML-201: Phase 2 open-label study to evaluate the efficacy and safety of intravenous administration of omacetaxine combined with the oral administration of imatinib mesylate (Gleevec®) in the treatment of patients with chronic myeloid leukemia (CML) in chronic, accelerated and blast phase.

Myelodysplastic Syndrome

CGX-635-MDS-201: Phase 2 open-label study to evaluate the efficacy and safety of intravenous administration of omacetaxine in the treatment of patients with myelodysplastic syndrome (MDS).

Solid Cancers

CGX-571-SOCA-101: Phase 1/2a open-label study to evaluate the efficacy and safety of intravenous administration of amonafide dihydrochloride (Quinamed®) in the treatment of patients with refractory prostate, breast and ovarian cancers who are refractory or resistant to existing therapies. The phase 2a trial seeks to confirm potential for dosing based on prospective genotyping of NAT2 genotype status.

Learn More

For further information on any of these studies you can log on to www.tkiresistantcml.com alternatively please contact the ChemGenex clinical trials group at our toll free number 1-800-877-3009 X 112 or e-mail us at clinical@chemgenex.com.

Disclosure of Risks

Please note that the safety and effectiveness of these products have not yet been established. As with other anti-cancer treatments, these investigational products may not benefit you and may cause side effects. These side effects could be severe or even life threatening. There may be side effects that are not known or predictable at this time, but that may occur at the time of treatment or later. You should discuss these risks with your physician or a study doctor.